On May 23, 2023, Sensei Biotherapeutics, Inc. entered into a Purchase Agreement with Apeiron Investment Group Ltd., Presight Sensei Co-Invest Fund, L.P., Presight Sensei Co-Invest Management, L.L.C., Christian Angermayer, Apeiron SICAV Ltd. - Presight Capital Fund ONE, and Altarius Asset Management Ltd. Apeiron Investment stated that it has also agreed to withdraw its notice of intent to nominate director candidates for election to the Company's Board of Directors at the 2023 annual meeting of stockholders, effective upon the closing of the purchase of the purchased shares.